Avivagen Inc.
VIVXF
$0.00
$0.000.00%
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -19.58% | -17.77% | -77.10% | 11,500.00% | -94.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.58% | -17.77% | -77.10% | 11,500.00% | -94.71% |
| Cost of Revenue | -39.61% | -18.75% | -77.34% | 1,702.10% | -95.13% |
| Gross Profit | 4.71% | -16.06% | -76.85% | 1,472.22% | -94.15% |
| SG&A Expenses | -71.16% | -43.99% | -40.18% | -3.96% | 15.47% |
| Depreciation & Amortization | -74.68% | -29.81% | -27.75% | -32.60% | -31.90% |
| Other Operating Expenses | -- | 48.48% | -43.59% | 81.33% | 51.85% |
| Total Operating Expenses | -70.56% | -42.65% | -44.44% | 30.99% | -17.60% |
| Operating Income | 72.24% | 44.31% | 35.81% | 12.44% | -58.83% |
| Income Before Tax | 52.69% | 10.69% | 30.15% | 28.21% | -50.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.69% | 10.69% | 30.15% | 28.21% | -50.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.69% | 10.69% | 30.15% | 28.21% | -50.22% |
| EBIT | 72.24% | 44.31% | 35.81% | 12.44% | -58.83% |
| EBITDA | 72.20% | 43.83% | 34.61% | 12.10% | -61.83% |
| EPS Basic | 61.54% | 31.21% | 48.37% | 9.17% | -35.26% |
| Normalized Basic EPS | 61.64% | 31.48% | 46.09% | -2.86% | -24.79% |
| EPS Diluted | 61.54% | 31.21% | 48.37% | 9.17% | -35.26% |
| Normalized Diluted EPS | 61.64% | 31.48% | 46.09% | -2.86% | -24.79% |
| Average Basic Shares Outstanding | 22.96% | 30.28% | 35.51% | -20.82% | 10.93% |
| Average Diluted Shares Outstanding | 22.96% | 30.28% | 35.51% | -20.82% | 10.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |